Covid USA: At least 628 ‘super variant’ cases reported in 33 states

At least 645 cases of coronavirus variants have been reported from the UK, South Africa and Brazil in 33 states.

Of that number, at least 626 are linked to the British variant known as B 1.1.7. reveals a DailyMail.com analysis of state and federal data.

More than half of those cases have been reported in Florida and California, and there are two deaths related to the species, one in New Jersey and one in Alabama.

Experts have warned that this variety is expected to become the dominant species in the US in March.

There are currently five cases of the B.1.351 variant, which was first discovered in South Africa, three of which are in Maryland and two in South Carolina.

In addition, two cases of the P.1 strain originating from Brazil have been identified in Minnesota.

It’s because cases in the US have declined by more than 50 percent, but the number of deaths continues to rise with more than 5,000 fatalities – the highest total in one day ever – recorded yesterday.

Due to the emergence of new variants, the U.S. Food and Drug Administration (FDA) announced on Thursday that it is developing guidelines to help vaccine, drug and test manufacturers adapt.

Acting Commissioner Janet Woodcock said that while all three can work now, there is a possibility that they will not in the future.

“We have to prepare for all eventualities,” she said during a telephone conversation with reporters.

In the coming weeks, Woodcock said the FDA will make draft recommendations to adjust products as needed.

In recent weeks, concerns have been raised about variants of the virus, which appear to be more contagious.

The British variant was first discovered in the county of Kent and now accounts for at least 61 cases in Great Britain.

Most estimates say it is about 70 percent more contagious, but some research suggests it could be twice as contagious.

More moderate projections say transferability is only about 56 percent higher.

Officials in the UK say the variant could be 30 to 40 percent more deadly, and so far there have been two deaths in the US related to the variant.

The South African variant was also first announced in December and shares mutation with the British variants, as well as several others.

President Joe Biden imposed a travel ban on people coming from South Africa in an attempt to stop imports of the new variety.

Dr. Anthony Fauci, the country’s top infectious disease expert, says the South African variety is the most concerning as it can make vaccines less effective because of mutations that help it ‘hide’ from antibodies developed after vaccination or a previous attack by COVID. 19.

The variant first drew international attention when four travelers arriving in Tokyo from Manaus, Brazil, tested positive on January 2.

The variant has the same peak protein mutation as the highly transferable versions found in Kent and South Africa – called N501Y – which makes the peak more able to bind to receptors in the body.

Manaus, the largest city in the Amazon, has been destroyed by COVID-19. Hospitals are running out of oxygen and Brazilian officials have said it is in crisis.

Preliminary findings suggest that all five major vaccine candidates offer some protection against the variants, but the extent has varied.

Two weeks ago, Moderna announced that while the vaccine still works well enough to protect against the South African variant, lab tests suggest that the antibodies activated by the injection may be 60 percent less potent against the virus in vitro (in a cell culture, not a live animal or person).

Last week, the results of Novavax’s late stage study in the UK showed 95.6 percent efficacy against the original circulating variant and 85.6 percent against B 1.1.7.

But in the South Africa mid-stage study of about 4,000 participants, the Novavax injection was not as protective and was found to be only 49.4% effective for its variant, 501Y.V2.

In an article published Friday, the vaccine developed by AstraZeneca and the University of Oxford was found to be 74 percent effective against B 1.1.7.

However, the findings did not address whether or not such protection applies to B.1.351.

Last week, Dr. Fauci at a press conference that the variants are expected to become more dominant in the US in the spring,

During the same briefing, Dr. Rochelle Walensky, director of the CDC, said that every COVID-19 case in the US should be treated as if it were a case of the variant.